Related Experiment Videos
Anti-inflammatory agents and antioxidants as a possible "third great wave" in cardiovascular secondary prevention
1Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA. bhattd@ccf.org
Insights
Despite statins and aspirin, cardiovascular disease persists. New therapies targeting inflammation and oxidative stress, like xanthophyll carotenoids, are crucial for improving outcomes in atherothrombotic disease.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Biochemistry
Background:
- Atherothrombotic disease is driven by plaque burden, hyperreactive platelets, and vascular inflammation.
- Statins and antiplatelet agents have reduced cardiovascular events but do not eliminate disease progression.
- A significant unmet need exists for novel therapies to improve outcomes in atherothrombotic disease.
Purpose of the Study:
- To analyze the role of inflammation and oxidative stress as therapeutic targets in atherothrombotic disease.
- To critically examine the history of anti-inflammatory and antioxidant therapies in cardiovascular disease.
- To explore contemporary drug discovery processes using xanthophyll carotenoids as an example.
Main Methods:
- Review of existing literature on atherothrombotic disease and its management.
- Analysis of the role of inflammation and oxidative stress in cardiovascular disease.
- Examination of the drug discovery and development pipeline for novel therapeutic agents.
Main Results:
- Inflammation and oxidative stress are increasingly recognized as critical factors in atherothrombosis.
- Past anti-inflammatory and antioxidant therapies have had limited success, necessitating new approaches.
- Xanthophyll carotenoids represent a promising class of antioxidants under investigation for cardiovascular benefits.
Conclusions:
- Targeting inflammation and oxidative stress holds potential for improving outcomes in atherothrombotic disease.
- Novel drug discovery approaches are essential to identify and develop effective therapies.
- Further research into agents like xanthophyll carotenoids is warranted to address the limitations of current treatments.
Abstract:
There are 3 important factors that predispose patients to plaque rupture or recurrent events: plaque burden or multiple arterial plaques, the presence of persistent hyperreactive platelets, and ongoing vascular arterial inflammation. Successful therapeutic strategies focus on these predisposing factors, and the use of low-density lipoprotein-lowering medications (principally statins) and antiplatelet agents (principally aspirin) has had a major impact on the occurrence of cardiovascular outcomes and overall mortality over the last 2 decades. However, despite these interventions, a significant number of patients experience recurrent events or progression of disease. Novel compounds are being studied to determine, for example, whether an increase in high-density lipoprotein will provide additional risk reduction; to date, this has not proved to be sufficiently effective. Although early invasive management has been proved to be superior to medical therapy in patients with plaque rupture producing acute coronary syndromes, its superiority in patients with clinically stable obstructive disease has been questioned. Thus, the search for additional agents to improve the outcomes of patients with atherothrombotic disease continues. The importance of inflammation, a potentially critical element in the initiation, progression, and rupture of plaque, has become increasingly evident. In this supplement, the role of inflammation and its principal cause, oxidative stress, are analyzed as potential targets of pharmacologic therapy. The history of anti-inflammatory and antioxidant therapy in cardiovascular disease is critically examined. Finally, the whole process of contemporary drug discovery and development from lead rationale and identification through biologic screening and testing in animals and then humans is explored, using as an example the xanthophyll carotenoids, a class of potent antioxidants currently under investigation.
Related Concept Videos
Atherosclerosis III: Management
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease IV: Preventive Measures
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Rheumatic Heart Disease III: Medical Management
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...